(Q37598084)
Statements
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma (English)
Jedd D Wolchok
Katherine S Panageas
Federica Catalanotti
David B Solit
Melissa P Pulitzer
Michael F Berger
Sasinya N Scott
Richard D Carvajal
Gary K Schwartz
Neal Rosen
Paul B Chapman
26 February 2013